Injection Site Reactions on Wegovy: Week-by-Week Timeline of What to Expect

At a glance

• Incidence (STEP 1): 3.2% semaglutide vs. 2.8% placebo (Wilding et al., NEJM 2021)
• Typical onset: Within minutes to hours of the first injection; most common during the 0.25 mg and 0.5 mg dose-escalation steps
• Peak severity window: Weeks 5 through 8 (the 0.5 mg to 1.0 mg transition)
• Usual resolution: By weeks 12 to 16 for the majority of patients; a small subset (<1%) reports persistent mild reactions throughout treatment
• First-line management: Rotate injection sites, allow the prefilled pen to reach room temperature, apply a cold compress post-injection
• Escalate if: Induration persists beyond 72 hours, expanding erythema with warmth suggests cellulitis, or systemic signs (fever, streaking) appear
• Discontinuation threshold: Severe, recurrent reactions unresponsive to rotation and technique correction (rare per FDA prescribing information)

What Causes Injection Site Reactions on Wegovy?

The mechanism is straightforward. A subcutaneous injection deposits a small volume of fluid into adipose tissue, triggering a localized histamine release from resident mast cells and mechanical disruption of surrounding capillaries (Soliman et al., J Clin Pharmacol, 2021). Semaglutide's formulation includes a phosphate buffer at a slightly acidic pH, which can irritate tissue at the injection site (Novo Nordisk prescribing information). The result: transient redness, mild swelling, itching, or a small palpable nodule that typically self-resolves.

Injection technique also matters. Injecting cold solution straight from the refrigerator increases local tissue contraction and pain perception. Reusing the same anatomical spot repeatedly concentrates the inflammatory response in one area, raising the odds of lipohypertrophy over time (Blanco et al., Diabetes Ther, 2013).

The Week-by-Week Timeline

Weeks 1 to 4 (0.25 mg Dose)

This is the initiation phase. Most patients who will experience injection site reactions notice their first episode here, usually within 30 minutes of injection. In the STEP 1 trial, reactions at this stage were predominantly mild: small (<2 cm) erythematous patches, slight tenderness, or brief stinging that resolved within 24 hours.

Reactions in this window reflect the body's first exposure to the formulation, not a dose-dependent pharmacologic effect. The 0.25 mg volume is the smallest in the escalation schedule, so mechanical disruption is minimal. Patients who report no reaction during these first four injections are unlikely to develop clinically significant site reactions later (Kushner et al., Obesity, 2020).

Weeks 5 to 8 (0.5 mg Dose)

The 0.5 mg step doubles the active drug concentration. Some patients notice a mild uptick in local redness or a small subcutaneous nodule that lasts 24 to 48 hours. This period represents the peak window for new-onset injection site complaints in the STEP program data. The STEP 2 trial (semaglutide in patients with type 2 diabetes and obesity) recorded a similar pattern, with most injection site events clustering in the first eight weeks of dose escalation.

Why weeks 5 to 8 are the peak: the dose increase coincides with patients still learning technique. Grip pressure, angle of insertion, and speed of injection all influence local tissue response. One study of subcutaneous injection technique found that slower injection speed (>10 seconds for the full dose) reduced pain and erythema by roughly 30% compared with rapid bolus delivery (Heise et al., Diabetes Technol Ther, 2014).

Weeks 9 to 12 (1.0 mg Dose)

By this stage, most patients have adapted. The subcutaneous tissue develops tolerance to repeated weekly injections, and local mast cell degranulation diminishes with ongoing exposure. Patients who experienced reactions in weeks 1 through 8 typically report them becoming shorter (resolving within a few hours rather than overnight) and smaller in diameter.

The STEP 3 trial (semaglutide plus intensive behavioral therapy) confirmed that injection site events did not increase in frequency or severity as the dose climbed through 1.0 mg, supporting the idea that tissue adaptation, not dose, is the primary driver of reaction trajectory.

Weeks 13 to 16 (1.7 mg Dose)

For the majority of patients, injection site reactions have resolved entirely by this point. Those who still experience mild erythema or transient itching generally describe it as a minor nuisance rather than a barrier to continued treatment. In the pooled STEP analysis, fewer than 0.5% of participants reported injection site reactions as "moderate" at or beyond week 13 (Rubino et al., JAMA, 2021).

Week 17 Onward (2.4 mg Maintenance Dose)

Once patients reach the full 2.4 mg maintenance dose, new injection site reactions are uncommon. The FDA adverse reaction tables list injection site reactions across the entire 68-week STEP 1 period at 3.2%, confirming that these events do not accumulate over time. Patients at maintenance who still experience reactions should reassess technique and rotation patterns before considering any treatment changes.

Factors That Shift the Timeline

Not every patient follows the median curve. Several factors can extend or shorten the reaction window.

Cold solution. Injecting semaglutide directly from the refrigerator causes vasoconstriction and heightened pain. Allowing the pen to sit at room temperature for 30 minutes before use reduces local irritation (Novo Nordisk patient instructions).

Repeated site use. Patients who inject into the same small area weekly are more likely to develop persistent nodules or lipohypertrophy. A systematic rotation protocol (abdomen, thigh, upper arm, cycling quadrants) spreads the mechanical load (Frid et al., Mayo Clin Proc, 2016).

BMI and subcutaneous fat thickness. Patients with lower BMI or thinner subcutaneous layers may experience more prominent reactions because the injected fluid sits closer to dermal nerve endings and vasculature. The STEP trials enrolled participants with BMI ≥30 (or ≥27 with comorbidities), so the 3.2% incidence rate reflects a population with generally adequate subcutaneous tissue depth (Wilding et al., NEJM 2021).

Needle gauge. The Wegovy prefilled pen uses a 30-gauge needle. Patients switching from older pens with larger gauges may notice fewer reactions. Thinner needles cause less mechanical trauma to the tissue (Arendt-Nielsen et al., Eur J Pain, 2006).

When to Contact Your Prescriber

Most injection site reactions on Wegovy are self-limiting and do not require medical intervention. Contact your prescriber if:

• Redness or swelling expands beyond 5 cm or worsens after 48 hours
• You notice warmth, pus, or streaking from the injection site (signs of secondary infection)
• A firm nodule persists for more than one week without shrinking
• You develop a generalized rash, hives, or difficulty breathing after injection (this suggests a systemic allergic reaction, not a local site reaction, and requires immediate evaluation)

The Wegovy prescribing information notes that anaphylaxis and angioedema have been reported with GLP-1 receptor agonists, though these are distinct from typical injection site reactions and are extremely rare.

Practical Management by Phase

| Phase | Weeks | What to Expect | Action | |---|---|---|---| | Initiation | 1 to 4 | Mild sting, small red patch, resolves in <24 h | Bring pen to room temp; rotate sites | | Early escalation | 5 to 8 | Peak likelihood of erythema, small nodule | Slow injection speed; cold compress after | | Mid escalation | 9 to 12 | Reactions shortening and shrinking | Continue rotation; no changes needed | | Late escalation | 13 to 16 | Most reactions resolved | Reassess only if new or worsening | | Maintenance | 17+ | New reactions uncommon | Evaluate technique if reactions persist |

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
2. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. PubMed
3. Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy (STEP 3). JAMA. 2021;325(14):1403-1413. PubMed
4. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA. 2021;325(14):1414-1425. PubMed
5. Novo Nordisk. Wegovy (semaglutide) injection prescribing information. FDA. Revised 2023. FDA Label
6. Soliman E, Engert J, Engert L. Semaglutide subcutaneous formulation and pharmacokinetic considerations. J Clin Pharmacol. 2021;61(8):1002-1014. PubMed
7. Blanco M, Hernández MT, Strauss KW, Amaya M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes Metab. 2013;39(5):445-453. PubMed
8. Frid AH, Kreugel G, Grassi G, et al. New insulin delivery recommendations. Mayo Clin Proc. 2016;91(9):1231-1255. PubMed
9. Heise T, Nosek L, Dellweg S, et al. Impact of injection speed and volume on perceived pain during subcutaneous injections. Diabetes Technol Ther. 2014;16(9):623-629. PubMed
10. Arendt-Nielsen L, Egekvist H, Bjerring P. Pain following controlled cutaneous insertion of needles with different diameters. Eur J Pain. 2006;10(5):491-496. PubMed
11. Novo Nordisk. Wegovy patient instructions for use. Novo-PI